SCIO-469

a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor for potential oral therapy for inflammatory disorders; in phase lib clinical trials for rheumatoid arthritis 4/2004

Networked: 12 relevant articles (4 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Higgins, Linda S: 6 articles (01/2010 - 06/2006)
2.	Medicherla, Satyanarayana: 6 articles (01/2010 - 06/2006)
3.	Protter, Andrew A: 5 articles (01/2010 - 05/2007)
4.	Kerr, Irene: 3 articles (01/2010 - 11/2008)
5.	Ma, Jing Y: 3 articles (06/2009 - 06/2006)
6.	Tong, Sandra E: 2 articles (05/2012 - 05/2011)
7.	Chakravarty, Sarvajit: 2 articles (06/2009 - 10/2008)
8.	Dugar, Sundeep: 2 articles (06/2009 - 10/2008)
9.	Navas, Tony A: 2 articles (11/2008 - 06/2006)
10.	Nguyen, Aaron N: 2 articles (11/2008 - 06/2006)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2008 - "Bone erosion and tumor growth were also examined but no significant reduction of bone erosion or tumor growth was observed in the SCIO-469 treated mice. " 11/01/2008 - "A significant dose-dependent reduction in RPMI-8226 tumor growth was also observed when SCIO-469 oral treatment at doses of 10, 30 and 90 mg/kg twice daily was initiated in mice with tumors of pronounced size, a condition that mimics advanced human myeloma disease. " 11/01/2008 - "In mice with palpable tumors, 14 days of SCIO-469 treatment significantly reduced RPMI-8226 tumor growth in a dose-dependent manner. " 11/01/2008 - "Oral treatment with SCIO-469 (10, 30, 90 mg/kg) twice daily was initiated in mice with palpable tumors of RPMI-8226 origin, a condition that mimics early human myeloma disease. " 11/01/2008 - "In a similar set of studies employing the SCIO-469 analogue SD-282 at 90 mg/kg/bid orally, histological assessment at the end of the study demonstrated a significant reduction in RPMI-8226 tumor growth and angiogenesis. "
2.	Rheumatoid Arthritis 11/01/2004 - "By July 2004, SCIO-469 was in phase lib clinical trials for rheumatoid arthritis." 05/01/2011 - "A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis." 05/01/2011 - "To evaluate the efficacy, safety, and tolerability of oral SCIO-469, a p38 MAPK inhibitor that blocks tumor necrosis factor-α, interleukin-1ß, and cyclooxygenase-2 synthesis in patients with active rheumatoid arthritis (RA). "
3.	Bone Marrow Failure Disorders 03/01/2007 - "These studies point to the potential efficacy of selective p38alpha inhibitor, SCIO-469, in human bone marrow failure."
4.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/01/2013 - "Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome."
5.	Multiple Myeloma 05/15/2007 - "In this study, we determined whether SCIO-469, a selective p38alpha MAPK inhibitor, inhibits multiple myeloma growth and prevents bone disease in the 5T2MM and 5T33MM models. "

Related Drugs and Biologics

1.	p38 Mitogen-Activated Protein Kinases
2.	indole-5-carboxamide (SD 282)
3.	Cyclooxygenase 2 (Cyclooxygenase-2)
4.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
5.	Mitogen-Activated Protein Kinases
6.	Interleukin-6 (Interleukin 6)
7.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
8.	Phosphotransferases (Kinase)
9.	Paraproteins
10.	Ibuprofen (Motrin)

Related Therapies and Procedures

1.	Therapeutics